-
Something wrong with this record ?
Hydrolytically degradable polymer micelles for drug delivery: a SAXS/SANS kinetic study
SK. Filippov, JM. Franklin, PV. Konarev, P. Chytil, T. Etrych, A. Bogomolova, M. Dyakonova, CM. Papadakis, A. Radulescu, K. Ulbrich, P. Stepanek, DI. Svergun,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24083567
DOI
10.1021/bm401186z
Knihovny.cz E-resources
- MeSH
- Acrylamides chemistry MeSH
- Time Factors MeSH
- Cholesterol chemistry MeSH
- X-Ray Diffraction MeSH
- Doxorubicin administration & dosage MeSH
- Hydrophobic and Hydrophilic Interactions MeSH
- Hydrolysis MeSH
- Kinetics MeSH
- Hydrogen-Ion Concentration MeSH
- Polymethacrylic Acids chemistry MeSH
- Drug Delivery Systems * MeSH
- Scattering, Small Angle MeSH
- Micelles * MeSH
- Molecular Structure MeSH
- Neutron Diffraction MeSH
- Surface Properties MeSH
- Antineoplastic Agents administration & dosage MeSH
- Particle Size MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We report kinetic studies of therapeutically highly potent polymer-drug conjugates consisting of amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based copolymers bearing the anticancer drug doxorubicin (Dox). Highly hydrophobic cholesterol moieties as well as the drug were attached to the polymer backbone by a pH-sensitive hydrazone bond. Moreover, the structure of the spacer between the polymer carrier and the cholesterol moiety differed in order to influence the release rate of the hydrophobic moiety, and thus the disintegration of the high-molecular-weight micellar nanoparticle structure. We performed time-dependent SAXS/SANS measurements after changing pH from a typical blood value (pH 7.2) to that of tumor cells (pH 5.0) to characterize the drug release and changes in particle size and shape. Nanoparticles composed of the conjugates containing Dox were generally larger than the drug-free ones. For most conjugates, nanoparticle growth or decay was observed in the time range of several hours. It was established that the growth/decay rate and the steady-state size of nanoparticles depend on the spacer structure. From analytical fitting, we conclude that the most probable structure of the nanoparticles was a core-shell or a core with attached Gaussian chains. We concluded that the spacer structure determined the fate of a cholesterol derivative after the pH jump. Fitting results for 5α-cholestan-3-onecholestan-3-one and cholesteryl-4-oxopentanoate (Lev-chol) implied that cholesterol moieties continuously escape from the core of the nanoparticle core and concentrate in the hydrophilic shell. In contrast, cholest-4-en-3-one spacer prevent cholesterol escaping. Dox moiety release was only observed after a change in pH. Such findings justify the model proposed in our previous paper. Lastly, the cholesteryl 4-(2-oxopropyl)benzoate (Opb-Chol) was a different case where after the release of hydrophobic Opb-Chol moieties, the core becomes more compact. The physicochemical mechanisms responsible for the scenarios of the different spacers are discussed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063926
- 003
- CZ-PrNML
- 005
- 20140707125025.0
- 007
- ta
- 008
- 140704s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/bm401186z $2 doi
- 035 __
- $a (PubMed)24083567
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Filippov, Sergey K $u Institute of Macromolecular Chemistry, AS CR , Heyrovsky Sq. 2, Prague, Prague 6, 162 06, Czech Republic.
- 245 10
- $a Hydrolytically degradable polymer micelles for drug delivery: a SAXS/SANS kinetic study / $c SK. Filippov, JM. Franklin, PV. Konarev, P. Chytil, T. Etrych, A. Bogomolova, M. Dyakonova, CM. Papadakis, A. Radulescu, K. Ulbrich, P. Stepanek, DI. Svergun,
- 520 9_
- $a We report kinetic studies of therapeutically highly potent polymer-drug conjugates consisting of amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based copolymers bearing the anticancer drug doxorubicin (Dox). Highly hydrophobic cholesterol moieties as well as the drug were attached to the polymer backbone by a pH-sensitive hydrazone bond. Moreover, the structure of the spacer between the polymer carrier and the cholesterol moiety differed in order to influence the release rate of the hydrophobic moiety, and thus the disintegration of the high-molecular-weight micellar nanoparticle structure. We performed time-dependent SAXS/SANS measurements after changing pH from a typical blood value (pH 7.2) to that of tumor cells (pH 5.0) to characterize the drug release and changes in particle size and shape. Nanoparticles composed of the conjugates containing Dox were generally larger than the drug-free ones. For most conjugates, nanoparticle growth or decay was observed in the time range of several hours. It was established that the growth/decay rate and the steady-state size of nanoparticles depend on the spacer structure. From analytical fitting, we conclude that the most probable structure of the nanoparticles was a core-shell or a core with attached Gaussian chains. We concluded that the spacer structure determined the fate of a cholesterol derivative after the pH jump. Fitting results for 5α-cholestan-3-onecholestan-3-one and cholesteryl-4-oxopentanoate (Lev-chol) implied that cholesterol moieties continuously escape from the core of the nanoparticle core and concentrate in the hydrophilic shell. In contrast, cholest-4-en-3-one spacer prevent cholesterol escaping. Dox moiety release was only observed after a change in pH. Such findings justify the model proposed in our previous paper. Lastly, the cholesteryl 4-(2-oxopropyl)benzoate (Opb-Chol) was a different case where after the release of hydrophobic Opb-Chol moieties, the core becomes more compact. The physicochemical mechanisms responsible for the scenarios of the different spacers are discussed.
- 650 _2
- $a akrylamidy $x chemie $7 D000178
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $7 D000970
- 650 _2
- $a cholesterol $x chemie $7 D002784
- 650 _2
- $a doxorubicin $x aplikace a dávkování $7 D004317
- 650 12
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a hydrolýza $7 D006868
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a kinetika $7 D007700
- 650 12
- $a micely $7 D008823
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a neutronová difrakce $7 D033363
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a kyseliny polymethakrylové $x chemie $7 D011109
- 650 _2
- $a maloúhlový rozptyl $7 D053838
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a difrakce rentgenového záření $7 D014961
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Franklin, John M
- 700 1_
- $a Konarev, Petr V
- 700 1_
- $a Chytil, Petr
- 700 1_
- $a Etrych, Tomas
- 700 1_
- $a Bogomolova, Anna
- 700 1_
- $a Dyakonova, Margarita
- 700 1_
- $a Papadakis, Christine M
- 700 1_
- $a Radulescu, Aurel
- 700 1_
- $a Ulbrich, Karel
- 700 1_
- $a Stepanek, Petr
- 700 1_
- $a Svergun, Dmitri I
- 773 0_
- $w MED00006456 $t Biomacromolecules $x 1526-4602 $g Roč. 14, č. 11 (2013), s. 4061-70
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24083567 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140707125314 $b ABA008
- 999 __
- $a ok $b bmc $g 1031410 $s 862658
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 14 $c 11 $d 4061-70 $i 1526-4602 $m Biomacromolecules $n Biomacromolecules $x MED00006456
- LZP __
- $a Pubmed-20140704